GLP-1 meds and food cravings from ads
Part of Hormones & metabolism clinical trials.
This study looks at how GLP-1 medications affect your food cravings and choices after seeing food ads. If you are taking tirzepatide, it could help researchers understand how these ads affect you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have overweight or obesity (BMI over 25)
- You take an injectable form of tirzepatide (like Mounjaro) at a dose of at least 7.5 mg as prescribed
- You are not taking any other similar medication besides your GLP-1 drug
- You speak English fluently
- You have a smartphone you can use for the study and do not have epilepsy or a cognitive or physical disability
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares how a GLP-1 medication (a drug that helps control blood sugar and weight) changes the way your body stores and uses fat. Researchers will use imaging scans to see these changes over time in people with metabolic syndrome—a cluster of health conditions including high blood pressure, high cholesterol, and excess weight.
This trial compares two ways to manage weight: taking a GLP-1 medication (like tirzepatide or semaglutide) versus making lifestyle changes without medication. It will help researchers learn which approach works best for people with overweight or obesity.
This study looks at how starting a GLP-1 medication (like Wegovy or Ozempic) changes your food choices and eating habits. It may help you understand if these medicines work for weight loss.
This study tests whether switching to an oral weight-loss medication can help you keep off the weight you lost after stopping a GLP-1 injection like semaglutide or tirzepatide. You might qualify if you live in Massachusetts, are between 18 and 80, have a BMI of 30 or higher, lost at least 10% of your body weight on these injections, and are willing to be randomly assigned to a new treatment.
This study tests the diabetes/weight-loss drug tirzepatide (Mounjaro) in young adults aged 18–26 who have obesity and either Prader-Willi syndrome, hypothalamic obesity, or general obesity. It looks at whether a weekly injection can help with weight management.
This study looks at how GLP-1 medications (like semaglutide/Wegovy or tirzepatide/Mounjaro) change your sense of taste and eating habits while losing weight. If you are 18–60, have obesity, and have been taking one of these drugs for at least 12 weeks, you may qualify.
Hear when a new GLP-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.